Fibrosis Progression Identified as Key Mortality Factor in MASLD
A recent study highlights fibrosis progression and systemic metabolic dysfunction as critical factors influencing mortality in MASLD.
Fibrosis stage is the strongest predictor of mortality in MASLD.
Cardiovascular mortality is more significant than liver-related mortality in affected patients.
Early identification of high-risk patients is crucial for better management of MASLD.
A systematic review and meta-analysis presented at the British Association for the Study of the Liver (BASL) Annual Meeting 2026 has identified fibrosis progression and systemic metabolic dysfunction as the primary drivers of mortality in metabolic dysfunction–associated steatotic liver disease (MASLD). The research, led by Syed Muhammad Hassan Bukhari from Darlington Memorial Hospital NHS England, analyzed data from 131 studies published between 2010 and 2026, focusing on predictors of mortality and adverse outcomes in MASLD patients.
The study aimed to evaluate various factors influencing mortality rates, particularly high-risk phenotypes, cardiometabolic burden, and fibrosis stage. Researchers utilized data from PubMed and PubMed Central, adhering to PRISMA guidelines for systematic reviews. They included studies that reported mortality outcomes for MASLD and its predecessor, nonalcoholic fatty liver disease (NAFLD). The analysis revealed that advanced fibrosis stages significantly correlated with increased all-cause and liver-related mortality.
Among the key findings, the Fibrosis-4 (FIB-4) score and noninvasive biomarkers were highlighted as predictive indicators of poor outcomes in MASLD patients. Notably, the study found that cardiovascular mortality rates surpassed liver-related mortality across the populations examined. The analysis identified several risk amplifiers, including chronic kidney disease (CKD) and type 2 diabetes (T2D), which further complicate the prognosis for these patients.
The implications of this research are significant for public health, particularly in the context of rising MASLD cases globally. The findings suggest that healthcare providers should prioritize early identification of high-risk patients to mitigate future disease burden. The study emphasizes the importance of assessing both fibrosis progression and cardiometabolic factors in the management of MASLD.
Looking ahead, the researchers advocate for enhanced risk stratification protocols in clinical settings to improve patient outcomes. They stress that understanding the interplay between fibrosis and metabolic dysfunction is essential for developing effective interventions and reducing mortality rates associated with MASLD.
